Expression and clinical significance of myocyte enhancer factor 2C in patients with gastric cancer
10.3760/cma.j.cn121382-20200510-00502
- VernacularTitle:肌细胞增强因子2C在胃癌患者中的表达及其临床意义
- Author:
Chengxiang SUN
1
;
Zhihai DING
Author Information
1. 天津医科大学中新生态城医院普外科 300467
- From:
International Journal of Biomedical Engineering
2020;43(5):349-353
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of myocyte enhancement factor 2C (MEF2C) protein in gastric cancer, and to study its relationship with pathology and prognosis.Methods:Using bioinformatics methods, the expression of MEF2C in gastric cancer patients and its relationship with overall survival were analyzed in the TCGA database. Sixty-six patients with gastric cancer were selected as the research object. The expression of MEF2C in gastric cancer was analyzed by immunohistochemical staining of postoperative gastric cancer tissue samples. By analyzing the expression of MEF2C in gastric cancer, combined with pathological information and postoperative follow-up information, the effect of MEF2C on the progression of gastric cancer was studied.Results:The high expression of MEF2C in gastric cancer tissue was related to tumor size and tumor recurrence (all P<0.05), but not related to tumor grade and lymph node metastasis (all P>0.05). Conclusions:The high expression of MEF2C protein can be used as a predictor for poor prognosis of gastric cancer.
